New cancer drug CFI-402257 enters first human trial

NCT ID NCT02792465

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It was the first time this drug was given to humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CFI-402257
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial, so the drug may not be effective or could have unexpected side effects. It is the first time CFI-402257 is tested in humans, so results are very preliminary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID CANCERS BREAST CANCER

Contacts and locations

Locations

BC Cancer Agency

Vancouver, British Columbia, V5Z 4E6, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
The Ottawa Hospital Cancer Centre

Ottawa, Ontario, K1H 8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.